NMN/NR and Sildenafil Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Combination Comes Up

NAD+ precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) have become two of the most widely purchased longevity supplements in the U.S. A 2024 market analysis estimated the global NMN supplement market exceeded $400 million in annual sales. Sildenafil (brand name Viagra), a phosphodiesterase type 5 inhibitor (PDE5i), remains one of the most prescribed medications for erectile dysfunction, with over 20 million U.S. prescriptions filled annually according to FDA postmarket surveillance data.

The overlap in demographics is significant. Men aged 40 to 65 who use sildenafil for ED are the same population most likely to adopt NAD+ supplementation for age-related metabolic decline. No published clinical trial has studied the two together, so the safety analysis below draws on each compound's known pharmacology, metabolism, and hemodynamic profile.

How NMN and NR Are Metabolized

NMN and NR enter the NAD+ salvage pathway through distinct but converging enzymatic steps. NR is phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) to form NMN, which is then adenylated by nicotinamide mononucleotide adenylyltransferases (NMNAT1-3) to produce NAD+ [1]. This pathway operates largely outside the hepatic cytochrome P450 system.

A key pharmacokinetic study by Airhart et al. (2017) demonstrated that NR at 1,000 mg/day for 8 days increased whole-blood NAD+ by approximately 100% without significant adverse events [2]. The compound's clearance depends on NRK-mediated phosphorylation and renal excretion of nicotinamide metabolites rather than CYP-mediated oxidation.

NMN follows a similar trajectory. A 2022 randomized, double-blind trial (N=80) by Yi et al. showed that NMN 250 mg/day for 12 weeks was well-tolerated in healthy middle-aged adults, with no clinically meaningful changes in liver transaminases or renal function markers [3]. The absence of CYP3A4, CYP2C9, or CYP2D6 involvement in NMN/NR metabolism is the single most important factor in assessing interaction risk with sildenafil.

How Sildenafil Is Metabolized

Sildenafil is primarily metabolized by CYP3A4 and, to a lesser extent, CYP2C9 [4]. Its active metabolite, N-desmethyl sildenafil, retains about 50% of the parent compound's PDE5 inhibitory activity. Peak plasma concentration occurs within 30 to 120 minutes, and the terminal half-life is approximately 3 to 5 hours.

Drugs that inhibit CYP3A4 (ketoconazole, ritonavir, erythromycin) increase sildenafil exposure substantially. The FDA label warns that co-administration with strong CYP3A4 inhibitors can raise sildenafil AUC by 11-fold. This is the mechanism behind most clinically significant sildenafil drug interactions.

NMN and NR have not been shown to inhibit or induce CYP3A4 in any published in vitro or in vivo study. A 2020 review of NAD+ precursor pharmacology in Annual Review of Pharmacology and Toxicology confirmed that nicotinamide-class compounds do not appear in standard CYP inhibition screening panels [5]. The pharmacokinetic interaction risk is therefore classified as negligible based on current evidence.

The Blood-Pressure Question: Where the Real Concern Lives

The more relevant concern is pharmacodynamic, not pharmacokinetic. Both compounds can reduce blood pressure through independent mechanisms.

Sildenafil inhibits PDE5, increasing cyclic GMP in vascular smooth muscle, which causes vasodilation. The FDA prescribing information reports a mean reduction of 8.4 mmHg systolic and 5.5 mmHg diastolic after a single 100 mg dose in healthy volunteers [4]. This effect is typically mild and transient. It becomes dangerous only when combined with nitrates (nitroglycerin, isosorbide mononitrate/dinitrate), which amplify the cGMP pathway synergistically and can cause life-threatening hypotension.

NMN may also modestly lower blood pressure. The Yi et al. trial found a 3.6 mmHg mean systolic reduction with 250 mg/day NMN over 12 weeks [3]. A separate study by Katayoshi et al. (2023, N=36) reported that NMN supplementation improved arterial stiffness measured by the cardio-ankle vascular index (CAVI) [6]. The proposed mechanism involves NAD+-dependent activation of sirtuins (particularly SIRT1), which upregulate endothelial nitric oxide synthase (eNOS) and improve endothelial function, as demonstrated in preclinical models published in Cell Metabolism [7].

The theoretical additive effect would be approximately 12 mmHg systolic in a patient taking both at standard doses. For a normotensive man with a baseline of 120/80 mmHg, this drop to roughly 108/74 mmHg is unlikely to cause symptoms. For a patient already on antihypertensives with a resting systolic below 110 mmHg, the additive reduction could produce dizziness, lightheadedness, or presyncope, especially during positional changes.

Sirtuin-PDE5 Crosstalk: A Mechanistic Note

One area of emerging research is the crosstalk between NAD+/sirtuin signaling and nitric oxide (NO) pathways. SIRT1 deacetylates and activates eNOS, increasing NO bioavailability [7]. PDE5 inhibitors work downstream of NO by preventing cGMP degradation. In theory, raising NAD+ levels with NMN/NR could increase upstream NO production while sildenafil extends the downstream signal.

This is not the same mechanism as the nitrate-PDE5i contraindication. Nitrates directly donate massive amounts of NO, overwhelming cGMP metabolism. The SIRT1-eNOS pathway produces a modest, physiologically regulated increase in NO. Dr. David Sinclair's laboratory at Harvard Medical School has published preclinical work showing that NMN restores endothelial function and capillary density in aged mice through SIRT1-dependent eNOS activation [7], but the magnitude of this effect in humans taking oral supplements is likely much smaller than pharmacologic nitrate exposure.

A 2018 study in Cell by Das et al. reported that NMN treatment in aged mice increased capillary density by 1.6-fold and improved exercise endurance by 80%, with effects mediated by SIRT1 and hydrogen sulfide signaling [7]. Translating murine vascular data to human hemodynamic predictions remains speculative.

P-glycoprotein and Transporter Considerations

Sildenafil is a substrate of P-glycoprotein (P-gp), the efflux transporter encoded by ABCB1. Drugs that inhibit P-gp can increase sildenafil absorption. NMN and NR have not been identified as P-gp inhibitors in published transporter assays [5]. NR is transported into cells primarily by equilibrative nucleoside transporters (ENTs), a separate transporter family with no known interaction with PDE5 inhibitor disposition [8].

This rules out the major non-CYP pharmacokinetic interaction pathway. The overall pharmacokinetic assessment remains: no identified mechanism for NMN/NR to alter sildenafil blood levels.

Who Should Be More Cautious

Most healthy men taking a standard NMN dose (250 to 500 mg/day) alongside sildenafil (25 to 100 mg as needed) face minimal additional risk. Specific populations that warrant closer attention include:

Patients on antihypertensives. Alpha-blockers (doxazosin, tamsulosin) already carry a labeled interaction with sildenafil. Adding an NAD+ precursor creates a third hypotensive input. The American Urological Association guidelines recommend a 4-hour dosing separation between alpha-blockers and PDE5 inhibitors [9]. Patients in this category should log home blood pressure readings for at least 14 days after starting NMN/NR.

Men taking high-dose NMN. Some consumer protocols exceed 1,000 mg/day. Human safety data above 1,200 mg/day are extremely limited. A phase I dose-escalation study by Liao et al. (2021, N=48) established safety of single NMN doses up to 1,200 mg, but hemodynamic effects at supratherapeutic doses were not systematically assessed [10].

Patients with autonomic dysfunction. Conditions like diabetic neuropathy or Parkinson disease impair baroreceptor reflexes. Even mild additive BP reductions can cause orthostatic hypotension in these populations.

Nitrate users. This is the absolute contraindication line, and it applies to sildenafil regardless of NMN/NR use. Sildenafil must not be taken within 24 hours of any nitrate formulation per FDA labeling [4].

Practical Monitoring Protocol

For patients who choose to use both NMN/NR and sildenafil, a reasonable monitoring approach includes:

Start NMN/NR at a low dose (250 mg/day) for 7 to 14 days before adding sildenafil. Measure resting blood pressure at the same time each morning. After establishing a stable baseline, take sildenafil at the usual prescribed dose and record blood pressure 1 hour after ingestion. A systolic reading below 90 mmHg or a drop exceeding 20 mmHg from baseline warrants discontinuation of one agent and physician consultation.

No dose adjustment of sildenafil is required solely because of NMN/NR co-administration, based on the absence of CYP3A4 or P-gp interactions. The Endocrine Society's 2018 guidelines on testosterone therapy note that PDE5i dose titration should be guided by clinical response and side effects rather than theoretical supplement interactions [11].

NMN/NR Supplement Quality: A Confounding Variable

One under-discussed risk in this combination is supplement purity. NMN and NR are classified as dietary supplements in the United States and are not subject to FDA premarket approval. A 2022 analysis published in the Journal of Dietary Supplements found that 30% of tested NMN products contained less than 80% of labeled dose, and some contained undisclosed excipients [12].

Contaminants or undeclared ingredients in low-quality supplements could introduce unpredictable pharmacokinetic interactions that pure NMN/NR would not. Third-party testing certifications (NSF International, USP Verified, ConsumerLab) reduce but do not eliminate this risk. Patients combining any supplement with a prescription medication should use products with verified purity documentation.

What the Clinical Literature Does Not Yet Tell Us

No human trial has measured:

• Sildenafil plasma levels before and after NMN/NR co-administration
• Ambulatory blood pressure monitoring during combined use
• Sexual function outcomes in men taking both agents
• Long-term cardiovascular event rates in dual users

Until dedicated interaction studies exist, the safety profile relies on mechanistic inference, single-agent pharmacokinetic data, and clinical pharmacology principles. The European Medicines Agency (EMA) and FDA drug interaction databases do not list NMN, NR, or nicotinamide mononucleotide as interacting substances with sildenafil [4].

The Bottom Line for Prescribers and Patients

The combination of NMN/NR and sildenafil does not trigger any known CYP, P-gp, or pharmacodynamic alarm at standard doses. The additive blood-pressure-lowering effect is real but modest in normotensive individuals. Patients on antihypertensives, alpha-blockers, or high-dose NMN protocols should perform home BP monitoring for 2 weeks after initiating the combination. Sildenafil's absolute contraindication with nitrates is unchanged by NMN/NR status. Use third-party-tested NMN/NR products, start at 250 mg/day, and report any lightheadedness or presyncope to your prescriber within 24 hours.